Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider Sells $19,050.71 in Stock

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) insider John Militello sold 833 shares of the stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $22.87, for a total value of $19,050.71. Following the completion of the transaction, the insider now owns 54,406 shares of the company’s stock, valued at approximately $1,244,265.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

John Militello also recently made the following trade(s):

• On Thursday, March 21st, John Militello sold 2,490 shares of Rocket Pharmaceuticals stock. The shares were sold at an average price of $28.10, for a total transaction of $69,969.00.
• On Thursday, February 29th, John Militello sold 10,000 shares of Rocket Pharmaceuticals stock. The stock was sold at an average price of $29.84, for a total transaction of $298,400.00.

Rocket Pharmaceuticals Stock Down 0.5 %

RCKT opened at $21.98 on Friday. The company has a market capitalization of $1.99 billion, a PE ratio of -7.48 and a beta of 1.07. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.80 and a quick ratio of 7.80. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $14.89 and a fifty-two week high of $32.53. The business has a 50-day moving average of $26.70 and a 200-day moving average of $25.41.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.14. During the same quarter in the prior year, the business posted ($0.92) EPS. Equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP increased its position in Rocket Pharmaceuticals by 56.0% during the third quarter. Wellington Management Group LLP now owns 8,022,830 shares of the biotechnology company’s stock worth $164,388,000 after buying an additional 2,880,373 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Rocket Pharmaceuticals by 18.3% during the 4th quarter. Vanguard Group Inc. now owns 5,447,565 shares of the biotechnology company’s stock worth $163,264,000 after acquiring an additional 843,552 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of Rocket Pharmaceuticals by 14.7% during the 3rd quarter. Westfield Capital Management Co. LP now owns 4,193,996 shares of the biotechnology company’s stock worth $85,935,000 after acquiring an additional 538,209 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Rocket Pharmaceuticals by 105.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 877,140 shares of the biotechnology company’s stock valued at $17,973,000 after acquiring an additional 449,569 shares during the last quarter. Finally, Comerica Bank bought a new position in shares of Rocket Pharmaceuticals in the 3rd quarter valued at approximately $9,017,000. Institutional investors own 98.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on RCKT shares. UBS Group decreased their price objective on shares of Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a research note on Friday, March 1st. StockNews.com raised Rocket Pharmaceuticals to a “sell” rating in a research report on Friday, February 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, February 27th. The Goldman Sachs Group began coverage on Rocket Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “neutral” rating and a $39.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $53.00 target price on shares of Rocket Pharmaceuticals in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $52.13.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.